Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients
- PMID: 25477303
- DOI: 10.1016/j.addr.2014.11.017
Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients
Abstract
Lung infection is the main cause of morbidity and mortality in patients with cystic fibrosis and is mainly dominated by Pseudomonas aeruginosa. The biofilm mode of growth makes eradication of the infection impossible, and it causes a chronic inflammation in the airways. The general mechanisms of biofilm formation and antimicrobial tolerance and resistance are reviewed. Potential anti-biofilm therapeutic targets such as weakening of biofilms by quorum-sensing inhibitors or antibiotic killing guided by pharmacokinetics and pharmacodynamics of antibiotics are presented. The vicious circle of adaptive evolution of the persisting bacteria imposes important therapeutic challenges and requires development of new drug delivery systems able to reach the different niches occupied by the bacteria in the lung of cystic fibrosis patients.
Keywords: Biofilm; Cystic fibrosis; Pseudomonas aeruginosa.
Copyright © 2014 Elsevier B.V. All rights reserved.
Similar articles
-
Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor.Antimicrob Agents Chemother. 2015 Dec 28;60(3):1676-86. doi: 10.1128/AAC.02533-15. Antimicrob Agents Chemother. 2015. PMID: 26711774 Free PMC article.
-
Targeting quorum sensing in Pseudomonas aeruginosa biofilms: current and emerging inhibitors.Future Microbiol. 2013 Jul;8(7):901-21. doi: 10.2217/fmb.13.57. Future Microbiol. 2013. PMID: 23841636 Review.
-
The problems of antibiotic resistance in cystic fibrosis and solutions.Expert Rev Respir Med. 2015 Feb;9(1):73-88. doi: 10.1586/17476348.2015.995640. Epub 2014 Dec 26. Expert Rev Respir Med. 2015. PMID: 25541089 Review.
-
Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.Curr Opin Pediatr. 2007 Feb;19(1):83-8. doi: 10.1097/MOP.0b013e3280123a5d. Curr Opin Pediatr. 2007. PMID: 17224667 Review.
-
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.Cochrane Database Syst Rev. 2012 Nov 14;11:CD009528. doi: 10.1002/14651858.CD009528.pub2. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2015 Mar 05;(3):CD009528. doi: 10.1002/14651858.CD009528.pub3. PMID: 23152277 Updated. Review.
Cited by
-
Mycobacterium abscessus biofilms have viscoelastic properties which may contribute to their recalcitrance in chronic pulmonary infections.Sci Rep. 2021 Mar 3;11(1):5020. doi: 10.1038/s41598-021-84525-x. Sci Rep. 2021. PMID: 33658597 Free PMC article.
-
Model-Informed Drug Discovery and Development in Pulmonary Delivery: Biopharmaceutical Pharmacometric Modeling for Formulation Evaluation of Pulmonary Suspensions.ACS Omega. 2020 Sep 22;5(40):25733-25746. doi: 10.1021/acsomega.0c03004. eCollection 2020 Oct 13. ACS Omega. 2020. PMID: 33073099 Free PMC article.
-
Azithromycin use in patients with cystic fibrosis.Eur J Clin Microbiol Infect Dis. 2015 Jun;34(6):1071-9. doi: 10.1007/s10096-015-2347-4. Epub 2015 Feb 17. Eur J Clin Microbiol Infect Dis. 2015. PMID: 25686729 Review.
-
Evolving serodiagnostics by rationally designed peptide arrays: the Burkholderia paradigm in Cystic Fibrosis.Sci Rep. 2016 Sep 12;6:32873. doi: 10.1038/srep32873. Sci Rep. 2016. PMID: 27615705 Free PMC article.
-
Multidrug resistant Pseudomonas aeruginosa in Estonian hospitals.BMC Infect Dis. 2018 Oct 11;18(1):513. doi: 10.1186/s12879-018-3421-1. BMC Infect Dis. 2018. PMID: 30309321 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical